approval
saveTALVEY (TALQUETAMAB-TGVS) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 7
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalMar 5, 2026 · 214d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalOct 2, 2025 · 368d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalAug 19, 2025 · 412d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalDec 2, 2024 · 672d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalFeb 20, 2024 · 958d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalNov 16, 2023 · 1054d ago
- approvalTALVEY (TALQUETAMAB-TGVS) — FDA approvalAug 9, 2023 · 1153d ago
same company · ±60 days · 6
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalJul 2, 2024
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalJul 9, 2024
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJul 30, 2024
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalAug 2, 2024
- approvalteclistamab: TECVAYLI (TECLISTAMAB-CQYV) — FDA approvalMay 28, 2024
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 19, 2024
comments(0)
5-min edit window · permanent after that